All AbMole products are for research use only, cannot be used for human consumption.
INO-1001 is a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. The present study tested INO-1001 for its in vivo effect on the chemoresponse of two p53 deficient tumors, human breast cancer MDA-MB-231 and murine mammary carcinoma MCa-K. Doxorubicin was used as the DNA damaging agent and tumor growth delay assay was used as the endpoint. Results showed that INO-1001 was highly effective in enhancing the anti-tumor effects of Doxorubicin for both MDA-MB-231 (EF=1.88) and MCa-K (EF=1.64).
Cell Death Dis. 2024 Jul 31;10(1):345.
Parthanatos initiated by ROS-induced DNA damage is involved in intestinal epithelial injury during necrotizing enterocolitis
INO-1001 purchased from AbMole
Bioact Mater. 2022 Feb 9.
pH and lipase-responsive nanocarrier-mediated dual drug delivery system to treat periodontitis in diabetic rats
INO-1001 purchased from AbMole
Cell Commun Signal. 2020 Feb 17;18(1):27.
mTOR May Interact With PARP-1 to Regulate Visible Light-Induced Parthanatos in Photoreceptors
INO-1001 purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | cultured podocytes |
Preparation method | Apoptosis detection. Apoptotic nuclei of cultured podocytes were detected on paraformaldehyde-fixed cells using DAPI (4′,6-diamidino-2-phenylindole) staining (1 μg/ml) for 10 min. Cells were analyzed under a fluorescence microscope and assessed for chromatin condensation and segregation. Caspase-3 activity was measured in podocyte extracts using EnzCheck Caspase-3 Assay kit (Molecular Probes) following the manufacturer’s protocol. Nuclear extracts were prepared using Transfactor DB Nuclear extraction kit (Clontech BD Bioscience) following the manufacturer’s protocol. Western blotting was performed using NFκB p50 (Santa Cruz Biotechnology) antibody. NFκB p50 nuclear binding assay was performed using TransFactor Colorimetric kit (Clontech BD) according to the manufacturer’s protocol. |
Concentrations | 200 nmol/l |
Incubation time | 45 min |
Animal Experiment | |
---|---|
Animal models | diabetic nephropathy of Leprdb/db mice model |
Formulation | sterile water |
Dosages | 60 mg/kg initiated at 5 weeks of age to around 8 weeks of age |
Administration | oral in drinking water |
Molecular Weight | 136.15 |
Formula | C7H8N2O |
CAS Number | 3544-24-9 |
Solubility (25°C) | DMSO 22 mg/mL Water ≥ 4 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related PARP Products |
---|
2-Methylquinazolin-4-ol
2-Methylquinazolin-4-ol is a potent competitive poly(ADP-ribose) synthetase inhibitor, with a Ki of 1.1 μM. 2-Methylquinazolin-4-ol mammalian aspartate transcarbamylase (ATCase) inhibitor, with IC50 of 0.20 mM. |
DPQ
DPQ is a potent PARP-1 inhibitor. |
OUL232
OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15. |
AZ3391
AZ3391 is a potent inhibitor of PARP. |
PARP1-IN-5
PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.